Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Rheumatology (Oxford, England)|June 11, 2026
T-cell subset biomarkers across the rheumatoid arthritis disease continuum: from clinical utility to adoption in daily practiceInnocent C Anioke, Fatih Tastekin, Gulay Alp, et al.
Annals of the Rheumatic Diseases|March 25, 2019
MRI inflammation of the hand interosseous tendons occurs in anti-CCP-positive at-risk individuals and may precede the development of clinical synovitisKulveer Mankia, Maria-Antonietta D'Agostino, Emma Rowbotham, et al.
Annals of the Rheumatic Diseases|July 21, 2021
Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritisFenne Wouters, Marc P Maurits, Laurette van Boheemen, et al.
RMD Open|October 6, 2025
Ultrasound-detected inflammation and structural changes in the joints, tendons and entheses of patients with cancer who developed arthritis or arthralgia after exposure to immune checkpoint inhibitorsAndrea Di Matteo, Kate Harnden, Sana Sharrack, et al.
Annals of the Rheumatic Diseases|September 26, 2025
Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritisPaula David, Tom Macleod, Ala Altaie, et al.
RMD Open|April 2, 2022
Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responsesBenazir Saleem, Rebecca L Ross, Lesley-Anne Bissell, et al.
BMJ Open|March 3, 2026
Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocolBenjamin A Fisher, Anna Rowe, Chris Hodson, et al.
Annals of the Rheumatic Diseases|August 7, 2021
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritisKulveer Mankia, Heidi J Siddle, Andreas Kerschbaumer, et al.
Nature Medicine|December 16, 2022
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanomaChelsea A Taylor, Robert A Watson, Orion Tong, et al.
The Lancet. Rheumatology|January 23, 2026
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
Pageof 8